-
Document de presse | 2022.02.02
New anti-HIV antibody function discovered: tethering of viral particles at the surface of cells
Teams at the Institut Pasteur, CNRS, Vaccine Research Institute (VRI) and Université de Paris have discovered a new function of anti-HIV-1[1] antibodies by applying cutting-edge microscopy techniques to in vitro viral cultures. The scientists found that certain antibodies already known for effectively targeting HIV-1 envelope (Env) protein can prevent infected cells from releasing viral particles...
-
Document de presse | 2022.03.29
SARS-CoV-2: neutralization of BA.1 and BA.2 by therapeutic monoclonal antibodies
The SARS-CoV-2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. Although Omicron is responsible for less severe forms in the general population, immunocompromised people are still at higher risk of developing severe forms of COVID-19. Several monoclonal antibodies are currently available in clinical practice as a preventive treatment for these patients....
-
Document de presse | 2022.04.12
HIV: The Antibodies of "Post-treatment Controllers"
A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their infection after interrupting all antiretroviral therapy.Understanding the fundamental mechanisms that govern their immune response is essential in order to develop HIV-1 vaccines, novel therapeutic strategies to achieve remission, or both.A recent study investigated the humoral...
-
News | 2022.06.08
The role of social sciences in the response to an epidemic: the example of the COVID-19 pandemic
A lesser known but equally crucial dimension in managing and responding to an epidemic is social sciences in health, which can shed light on populations' understanding, perception and acceptance of the risks associated with diseases. The COVID-19 pandemic is no exception. As the disease spread across the planet, clear differences in perception by populations were observed in different countries,...
-
News | 2022.06.14
A New Drug Target against Malaria
Malaria is a disease that continues to cause tremendous suffering and mortality in the tropics. This disease is caused by Plasmodium parasites. The species Plasmodium falciparum causes the severest and most deadly form of malaria. Scientists from Institut Pasteur studied the blood stage of the parasites and found a mechanism which could lead to new and efficient drugs against Malaria.Despite...
-
Article | 2024.04.30
Edmond Nocard, discoverer of the Nocardia bacterium
Veterinarian and biologist, this disciple of Louis Pasteur pioneered the study of microbial animal diseases and is considered the founder of veterinary microbiology.
-
News | 2022.07.09
Conversation: capacity building to prepare for the future
Institut Pasteur Senior Executive Scientific Vice-President Christophe d'Enfert provides a brief, cross-disciplinary overview of 2021 covering capacity building, enhanced partnerships and future technologies.
-
Article | 2023.12.18
Interdisciplinary Training in Genomic Epidemiology and Public Health Bioinformatics
This interdisciplinary programme, funded by ECDC, combines lectures and practical sessions delivered by multiple host institutions in order to enhance surveillance, preparedness, and readiness to respond to outbreaks.
-
Document de presse | 2012.09.26
Malaria Takes a Hit – Two New Molecules Stop P. falciparum in its Tracks
Researchers at the Institut Pasteur and the French National Center for Scientific Research (CNRS), in collaboration with Imperial College London, have synthesized two molecules capable of quickly and irreversibly stopping the growth of P. falciparum at every blood stage of its life cycle. These molecules work by inhibiting the histone methyltransferase enzymes necessary for the parasite’s...
-
Document de presse | 2005.10.12
Institut Pasteur and Total join forces to combat infectious diseases
On October 13, Total and Institut Pasteur signed a corporate funding agreement intended to strengthen the scientific and human resources allocated to the fight against infectious diseases, especially sexually transmitted diseases (STD). The five-year agreement covers two areas. Press release Paris, october 13, 2005 · Support for Institut Pasteur’s research...